Hemorrhoidal disease: is it time for a new classification?

Rubbini, Michele; Ascanelli, Simona; Fabbian, Fabio

doi:10.1007/s00384-018-3060-4

Cited by 14 publications

(12 citation statements)

References 11 publications

Supporting

Mentioning

Contrasting

Unclassified

Order By: Relevance

“…HD is a well-de ned clinical and pathophysiological placement between benign conditions but with high impact on quality of life [12] . Bleeding is the main symptom of HD [4] .…”

Section: Discussionmentioning

confidence: 99%

Chinese Classical Prescription(Liang-Xue-Di-Huang Decoction)for Hemohhhoidal Disease:study protocol for a randomized controlled trial

Zhou

Shi

et al. 2020

Preprint

View full text Add to dashboard Cite

Background: Hemorrhoidal disease (HD) is one of the commonest proctologic condition in the general population. Medical therapy for HD has not been formally confirmed due to the inconsistent of results. Liang-Xue-Di-Huang Decoction, a kind of ancient Chinese classical prescription, has been used to treat HD from the 19th century in China. However, clinical research of Liang-Xue-Di-Huang Decoction in the treatment of HD is lack. We designed this study to evaluate the efficacy and safety of Liang-Xue-Di-Huang Decoction in the treatment of HD. Methods/Design: A randomized, controlled, double blind, double-mimetic agent and multicenter trial to evaluate the efficacy and safety of Liang-Xue-Di-Huang Decoction is proposed. HD patients (stage I, Ⅱ, Ⅲ) will be randomly assigned into Liang-Xue-Di-Huang Decoction with the addition of Diosmine mimetic agent, or Diosmine with the addition of Liang-Xue-Di-Huang Decoction mimetic agent. Patients will receive a 7-days treatments and a 7-days follow-up. The primary outcome measure is the French Bleeding Score in 7 and 14 days. The Secondary outcome measures are Goligher Prolapse Score and Quality-of-Life Score in 7 and 14 days. Discussion: This study will provide objective evidence to evaluate the efficacy and safety of Liang-Xue-Di-Huang Decoction in treatment of HD. Trial registration: Chinese Clinical Trial Registry. ChiCTR-1900022531.Registered 15 Apr 2019, http://www.chictr.org.cn/listbycreater.aspx.

show abstract

“…HD is a well-de ned clinical and pathophysiological placement between benign conditions but with high impact on quality of life [12] . Bleeding is the main symptom of HD [4] .…”

Section: Discussionmentioning

confidence: 99%

Chinese Classical Prescription(Liang-Xue-Di-Huang Decoction)for Hemohhhoidal Disease:study protocol for a randomized controlled trial

Zhou

Shi

et al. 2020

Preprint

View full text Add to dashboard Cite

show abstract

“…HD is a well-defined clinical and pathophysiological placement between benign conditions but with high impact on quality of life [12] . Chronic bleeding is the main symptom of HD [4] .…”

Section: Discussionmentioning

confidence: 99%

Chinese Classical Prescription (Liang-Xue-Di-Huang Decoction) for Hemorrhoidal Disease: study protocol for a randomized controlled trial

Zhou

Shi

et al. 2019

Preprint

View full text Add to dashboard Cite

Background: Hemorrhoidal disease (HD) is one of the commonest proctologic condition in the general population. Medical therapy for HD has not been formally confirmed due to the inconsistent of results. Liang-Xue-Di-Huang Decoction, a kind of ancient Chinese classical prescription, has been used to treat HD from the 19th century in China. However, clinical research of Liang-Xue-Di-Huang Decoction in the treatment of HD is lack. We designed this study to evaluate the efficacy and safety of Liang-Xue-Di-Huang Decoction in the treatment of HD. Methods/Design: A randomized, controlled, double blind, double-mimetic agent and multicenter trial to evaluate the efficacy and safety of Liang-Xue-Di-Huang Decoction is proposed. HD patients (stage I, Ⅱ, Ⅲ) will be randomly assigned into Liang-Xue-Di-Huang Decoction with the addition of Diosmine mimetic agent group and Diosmine with the addition of Liang-Xue-Di-Huang Decoction mimetic agent group. Patients will receive a 7-day treatments and a 7-day follow-up. The primary outcome measure is the French Bleeding Score in 7 and 14 days. The Secondary outcome measures are Goligher Prolapse Score and Quality-of-Life Score in 7 and 14 days. Discussion: This study will provide objective evidence to evaluate the efficacy and safety of Liang-Xue-Di-Huang Decoction in treatment of HD. Trial registration: Chinese Clinical Trial Registry. ChiCTR-1900022531.Registered 19 Apr 2019, http://www.chictr.org.cn/listbycreater.aspx. Keywords: Hemorrhoidal disease, Liang-Xue-Di-Huang Decoction, Chinese classical prescription, Randomized controlled trial.

show abstract

“…Hemorrhoidal disease (HD) is one of the most common anorectal conditions of adulthood. It is estimated to affect approximately 4% of the population, with 50% of people over 50 years-old referring to related symptoms at some point in life [1][2][3]. Although it is a benign condition, it generates a social burden (as it impacts lifestyle), an economic burden (on health systems), and a social security burden (by the working days lost or harmed by the disease itself) [2].…”

Section: Introductionmentioning

confidence: 99%

“…Despite this modernization, the classification of symptomatic hemorrhoids has not been updated since the publication of the Goligher classification. Many surgical techniques (which are largely used) are not factored into Goligher classification, which is considered to be anachronistic since it may not be able to guide and evaluate the outcomes of the treatment [2,3].…”

Section: Introductionmentioning

confidence: 99%

A New Classification for Hemorrhoidal Disease: The Creation of the “BPRST” Staging and Its Application in Clinical Practice

et al. 2020

View full text Add to dashboard Cite

Purpose: Present an updated classification for symptomatic hemorrhoids, which not only guides the treatment of internal hemorrhoids but also the treatment of external components. In addition, this new classification includes new treatment alternatives created over the last few years.Methods: Throughout the past 7 years, the authors developed a method to classify patients with symptomatic hemorrhoids. This study, besides presenting this classification proposal, also retrospectively analyzed 149 consecutive patients treated between March 2011 and November 2013 and aimed to evaluate the association between the management adopted with Goligher classification and our proposed BPRST classification.Results: Both classifications had a statistically significant association with the adopted management strategies. However, the BPRST classification tended to have fewer management discrepancies when each stage of disease was individually analyzed.Conclusion: Although there is much disagreement about how the classification of hemorrhoidal disease should be updated, it is accepted that some kind of revision is needed. The BPRST method showed a strong association with the management that should be adopted for each stage of the disease. Further studies are needed for its validation, but the current results are encouraging.

show abstract

Hemorrhoidal disease: is it time for a new classification?

Cited by 14 publications

References 11 publications

Chinese Classical Prescription(Liang-Xue-Di-Huang Decoction)for Hemohhhoidal Disease:study protocol for a randomized controlled trial

Chinese Classical Prescription(Liang-Xue-Di-Huang Decoction)for Hemohhhoidal Disease:study protocol for a randomized controlled trial

Chinese Classical Prescription (Liang-Xue-Di-Huang Decoction) for Hemorrhoidal Disease: study protocol for a randomized controlled trial

A New Classification for Hemorrhoidal Disease: The Creation of the “BPRST” Staging and Its Application in Clinical Practice

Contact Info

Product

Resources

About